These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11886813)

  • 1. The discovery of YM-60828: a potent, selective and orally-bioavailable factor Xa inhibitor.
    Hirayama F; Koshio H; Katayama N; Kurihara H; Taniuchi Y; Sato K; Hisamichi N; Sakai-Moritani Y; Kawasaki T; Matsumoto Y; Yanagisawa I
    Bioorg Med Chem; 2002 May; 10(5):1509-23. PubMed ID: 11886813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological activity of YM-60828 derivatives. Part 2: potent and orally-bioavailable factor Xa inhibitors based on benzothiadiazine-4-one template.
    Hirayama F; Koshio H; Katayama N; Ishihara T; Kaizawa H; Taniuchi Y; Sato K; Sakai-Moritani Y; Kaku S; Kurihara H; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2003 Feb; 11(3):367-81. PubMed ID: 12517432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological activity of YM-60828 derivatives: potent and orally-bioavailable factor Xa inhibitors based on naphthoanilide and naphthalensulfonanilide templates.
    Hirayama F; Koshio H; Ishihara T; Watanuki S; Hachiya S; Kaizawa H; Kuramochi T; Katayama N; Kurihara H; Taniuchi Y; Sato K; Sakai-Moritani Y; Kaku S; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2002 Aug; 10(8):2597-610. PubMed ID: 12057649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of R-142086 as a factor Xa (FXa) inhibitor: syntheses and structure-activity relationships of cinnamyl derivatives.
    Noguchi T; Tanaka N; Nishimata T; Goto R; Hayakawa M; Sugidachi A; Ogawa T; Niitsu Y; Asai F; Ishizuka T; Fujimoto K
    Chem Pharm Bull (Tokyo); 2009 Jan; 57(1):22-33. PubMed ID: 19122312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the anticoagulant and antithrombotic effects of YM-75466, a novel orally-active factor Xa inhibitor, and warfarin in mice.
    Sato K; Taniuchi Y; Kawasaki T; Hirayama F; Koshio H; Matsumoto Y; Iizumi Y
    Jpn J Pharmacol; 1998 Oct; 78(2):191-7. PubMed ID: 9829622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of arterial thrombosis.
    Kawasaki T; Sato K; Sakai Y; Hirayama F; Koshio H; Taniuchi Y; Matsumoto Y
    Thromb Haemost; 1998 Feb; 79(2):410-6. PubMed ID: 9493600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa.
    Taniuchi Y; Sakai Y; Hisamichi N; Kayama M; Mano Y; Sato K; Hirayama F; Koshio H; Matsumoto Y; Kawasaki T
    Thromb Haemost; 1998 Mar; 79(3):543-8. PubMed ID: 9531037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of N-[(1R,2S,5S)-2-{[(5-chloroindol-2-yl)carbonyl]amino}-5-(dimethylcarbamoyl)cyclohexyl]-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide hydrochloride: a novel, potent and orally active direct inhibitor of factor Xa.
    Nagata T; Yoshino T; Haginoya N; Yoshikawa K; Nagamochi M; Kobayashi S; Komoriya S; Yokomizo A; Muto R; Yamaguchi M; Osanai K; Suzuki M; Kanno H
    Bioorg Med Chem; 2009 Feb; 17(3):1193-206. PubMed ID: 19128974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor.
    Hara T; Yokoyama A; Morishima Y; Kunitada S
    Thromb Res; 1995 Oct; 80(1):99-104. PubMed ID: 8578544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats.
    Sato K; Taniuchi Y; Kawasaki T; Hirayama F; Koshio H; Matsumoto Y
    Eur J Pharmacol; 1998 Apr; 347(2-3):231-6. PubMed ID: 9653887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins.
    Rezaie AR
    Thromb Haemost; 2003 Jan; 89(1):112-21. PubMed ID: 12540961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dibasic (amidinoaryl)propanoic acid derivatives as novel blood coagulation factor Xa inhibitors.
    Nagahara T; Yokoyama Y; Inamura K; Katakura S; Komoriya S; Yamaguchi H; Hara T; Iwamoto M
    J Med Chem; 1994 Apr; 37(8):1200-7. PubMed ID: 8164262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orally active factor Xa inhibitor: synthesis and biological activity of masked amidines as prodrugs of novel 1,4-diazepane derivatives.
    Koshio H; Hirayama F; Ishihara T; Kaizawa H; Shigenaga T; Taniuchi Y; Sato K; Moritani Y; Iwatsuki Y; Uemura T; Kaku S; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2004 Oct; 12(20):5415-26. PubMed ID: 15388168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of sulfonylalkylamides: A new class of orally active factor Xa inhibitors.
    Imaeda Y; Miyawaki T; Sakamoto H; Itoh F; Konishi N; Hiroe K; Kawamura M; Tanaka T; Kubo K
    Bioorg Med Chem; 2008 Mar; 16(5):2243-60. PubMed ID: 18077174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors.
    Shi Y; Zhang J; Shi M; O'Connor SP; Bisaha SN; Li C; Sitkoff D; Pudzianowski AT; Chong S; Klei HE; Kish K; Yanchunas J; Liu EC; Hartl KS; Seiler SM; Steinbacher TE; Schumacher WA; Atwal KS; Stein PD
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4034-41. PubMed ID: 19541481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombotic effects of YM-60828 in three thrombosis models in guinea pigs.
    Sato K; Kawasaki T; Hisamichi N; Taniuchi Y; Hirayama F; Koshio H; Ichihara M; Matsumoto Y
    Eur J Pharmacol; 1998 May; 350(1):87-91. PubMed ID: 9683019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological activity of amidinobicyclic compounds (derivatives of DX-9065a) as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
    Komoriya S; Kanaya N; Nagahara T; Yokoyama A; Inamura K; Yokoyama Y; Katakura S; Hara T
    Bioorg Med Chem; 2004 May; 12(9):2099-114. PubMed ID: 15080912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577.
    Shi Y; Li C; O'Connor SP; Zhang J; Shi M; Bisaha SN; Wang Y; Sitkoff D; Pudzianowski AT; Huang C; Klei HE; Kish K; Yanchunas J; Liu EC; Hartl KS; Seiler SM; Steinbacher TE; Schumacher WA; Atwal KS; Stein PD
    Bioorg Med Chem Lett; 2009 Dec; 19(24):6882-9. PubMed ID: 19896847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
    Morishima Y; Tanabe K; Terada Y; Hara T; Kunitada S
    Thromb Haemost; 1997 Nov; 78(5):1366-71. PubMed ID: 9408021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cinnamylindoline derivatives: synthesis and factor Xa (FXa) inhibitory activities.
    Noguchi T; Tanaka N; Nishimata T; Goto R; Hayakawa M; Sugidachi A; Ogawa T; Asai F; Fujimoto K
    Chem Pharm Bull (Tokyo); 2007 Oct; 55(10):1494-504. PubMed ID: 17917295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.